Fosfomycin calcium

Research use only, not for human use.

Fosfomycin calcium is an antibiotics, used in urinary tract infections and intestinal infections caused by susceptible strains.

Fosfomycin calcium is an antibiotics, used in urinary tract infections and intestinal infections caused by susceptible strains. (In Vitro):Fosfomycin calcium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin calcium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin calcium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.(In Vivo):Fosfomycin calcium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes.

Fosfomycin calcium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin calcium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin calcium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.

Fosfomycin calcium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes.Pharmacokinetic of Fosfomycin calcium in RatsAnimal Model:Fischer 344 ratsDosage:320 mg/kg Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old) Dosage:120 mg/kg Administration: Intravenous injection; once Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters. Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.

Calcium fosfomycin | AN-8336 | CS-4631 | AN8336 | CS4631

GPCR/G Protein

Antibacterial

Others

Infection

——

26016-98-8

176.12

C3H5CaO4P

>98% (HPLC)

Water: 10 mM

C[C@H]1[C@@H](P(O)([O-])=O)O1.CC2C(P(O)([O-])=O)O2.[Ca+2]

calcium hydrogen ((2R,3S)-3-methyloxiran-2-yl)phosphonate hydrogen (3-methyloxiran-2-yl)phosphonate

(-20℃)

With Ice Pack

≥ 2 years